Thursday, 20 November 2025
  
Login

Australia's most trusted
source of pharma news

Thursday, 20 November 2025
News

Top drugs expanding their patch

Posted 20 November 2025 AM

Almost half of the 22 changes to existing listings that the PBAC will consider in March are to add a new cancer or other new indication, with ten drugs looking to expand into new diseases.

Two pharmas are seeking funding for the interleukin blockers to treat chronic obstructive pulmonary disease. Sanofi's Dupixent will be considered for use as add-on maintenance treatment for uncontrolled COPD in adult patients with raised blood eosinophils and on a stable combination of drugs, while GSK's Nucala will be considered for use in combination with other drugs for the treatment of adult patients with COPD characterised by an eosinophilic phenotype who continue to experience exacerbations.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (13)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (5)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.